Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS

The presence of carcinoma in situ (CIS) is traditionally a contraindication to bladder-sparing approaches for muscle invasive bladder cancer (MIBC). Strategies that might aid in bladder preservation for this population require further investigation. We report a case of MIBC with CIS treated with bot...

Full description

Saved in:

Bibliographic Details
Published in:	Urology case reports Vol. 50; p. 102516
Main Authors:	Plambeck, Benjamin D., Tazegul, Tutku E., McElree, Ian M., Steinberg, Ryan L., Packiam, Vignesh T., O'Donnell, Michael A.
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 01-09-2023 Elsevier
Subjects:	Carcinoma in situ Docetaxel Gemcitabine Muscle invasive bladder cancer Oncology Partial cystectomy Carcinoma in situ Gemcitabine NMIBC TURBT Docetaxel Muscle invasive bladder cancer CIS Partial cystectomy CT Gem/Doce UCC FISH MIBC
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The presence of carcinoma in situ (CIS) is traditionally a contraindication to bladder-sparing approaches for muscle invasive bladder cancer (MIBC). Strategies that might aid in bladder preservation for this population require further investigation. We report a case of MIBC with CIS treated with both neoadjuvant systemic and intravesical chemotherapy prior to partial cystectomy.
ISSN:	2214-4420 2214-4420
DOI:	10.1016/j.eucr.2023.102516